Recombinant Mouse TNFRSF18 Protein (Met1-His153), MlgG1 Fc-tagged
Cat.No. : | TNFRSF18-894M |
Product Overview : | Recombinant Mouse TNFRSF18 Protein (NP_033426.1) (Met1-His153) was produced by HEK293 Cells expression system. This protein was expressed with the Fc region of mouse IgG1 at the C-terminus. |
Availability | February 10, 2025 |
Unit | |
Price | |
Qty |
- Specification
- Gene Information
- Related Products
- Download
Description : | GITR, also known as TNFRSF18(CD357), belongs to the tumor necrosis factor receptor (TNF-R) superfamily. It is the receptor for TNFSF18. GITR plays a key role in dominant immunological self-tolerance maintained by CD25(+)CD4(+) regulatory T cells. GITR may be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. GITR and its ligand are important costimulatory molecules in the pathogenesis of autoimmune diseases. It also mediates NF-kappa-B activation via the TRAF2/NIK pathway. |
Source : | HEK293 |
Species : | Mouse |
Tag : | mFc |
Predicted N Terminal : | Gln 20 |
Form : | Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. |
Molecular Mass : | The recombinant mouse TNFRSF18 consists of 368 amino acids and predicts a molecular mass of 41 kDa. |
Protein length : | Met1-His153 |
Endotoxin : | < 1.0 EU per μg protein as determined by the LAL method. |
Purity : | > 95 % as determined by SDS-PAGE. |
Stability : | Samples are stable for up to twelve months from date of receipt at -70 centigrade. |
Storage : | Store it under sterile conditions at -20 centigrade to -80 centigrade. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 mg/ml. Centrifuge the vial at 4℃ before opening to recover the entire contents. |
Shipping : | In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise. |
Gene Name : | Tnfrsf18 tumor necrosis factor receptor superfamily, member 18 [ Mus musculus ] |
Official Symbol : | TNFRSF18 |
Synonyms : | TNFRSF18; AITR; Gitr; |
Gene ID : | 21936 |
mRNA Refseq : | NM_009400 |
Protein Refseq : | NP_033426 |
UniProt ID : | O35714 |
Products Types
◆ Recombinant Protein | ||
TNFRSF18-1611C | Recombinant Cynomolgus TNFRSF18 protein, His-tagged | +Inquiry |
TNFRSF18-661H | Recombinant Human TNFRSF18 Protein | +Inquiry |
TNFRSF18-662M | Recombinant Mouse TNFRSF18 Protein | +Inquiry |
Tnfrsf18-666R | Recombinant Rhesus macaque Tnfrsf18 Protein, Fc-tagged | +Inquiry |
TNFRSF18-9477M | Recombinant Mouse TNFRSF18 Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Lysates | ||
TNFRSF18-1245RCL | Recombinant Rat TNFRSF18 cell lysate | +Inquiry |
TNFRSF18-1143HCL | Recombinant Human TNFRSF18 cell lysate | +Inquiry |
Related Gene
Not For Human Consumption!
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewThis flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.
Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.
The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.
Q&As (5)
Ask a questionClinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.
As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.
Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.
TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.
Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.
Ask a Question for All TNFRSF18 Products
Required fields are marked with *
My Review for All TNFRSF18 Products
Required fields are marked with *
Inquiry Basket